This subtype of breast cancer, named for its lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and HER2, is not amenable to targeted therapy directed at the ER and HER2, leaving patients to rely on chemotherapy as the standard of care [2,3]. The gene discussed is ESR1; the disease is breast cancer.